Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-708 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A: VX-708 (Cohort A1-A3) | EXPERIMENTAL | Participants will receive multiple doses of one of different dose levels of VX-708 under fasting condition. |
| Part A: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to VX-708. |
| Part A: Midazolam With or Without VX-708 (Cohort A4) | EXPERIMENTAL | Participants will receive a single dose of Midazolam with or without VX-708 under fasting condition. |
| Part B: VX-708 With Itraconazole | EXPERIMENTAL | Participants will receive a single dose of VX-708 in treatment period 1, followed by itraconazole, which will be dosed daily with a single dose of VX-708 administered in treatment period 2 under fasting conditions. A washout period of 6 days will be maintained between the 2 treatment periods. |
| Part A: VX-708 | EXPERIMENTAL | Participants will be randomized to receive a single dose of different dose levels of VX-708. |
| Part B: VX-708 | EXPERIMENTAL | Participants will be randomized to receive multiple doses of different dose levels of VX-708. The dose levels will be determined based on the data from Part A. |
| Part B: Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matched to VX-708. |
| Name | Type | Description |
|---|---|---|
| VX-708 | DRUG | Solution for intravenous (IV) administration. |
| Itraconazole | DRUG | Solution for oral administration. |
| Midazolam | DRUG | Solution for oral administration. |
| Placebo | DRUG | Placebo matched to VX-708 for IV administration. |
Key Inclusion Criteria: * Male and female of non-childbearing potential are eligible * Body mass index (BMI) of 18.0 to 32.0 kilograms per meter square (kg/m\^2) * A total body weight greater than (\>) 50 kg Key Exclusion Criteria: * History of febrile illness or other acute illness within 14 day...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
VX-708 is an investigational small molecule being developed for the treatment of acute pain and pain. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
VX-708 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX.
VX-708 is in Phase 1 clinical development. Two Phase 1 dose escalation studies in healthy participants have been completed, but the drug remains investigational and has not received regulatory approval.
VX-708 has been studied in two completed Phase 1 trials: NCT05347394, a dose escalation study in healthy participants in the United Kingdom, and NCT05518734, a similar study in the United States. Both trials were randomized, double-blind, and placebo-controlled.
No alternative names for VX-708 have been disclosed. It is identified solely by its development code VX-708 and is being studied as a monotherapy for pain indications.